YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.

ABSTRACT:

Introduction

The clinical and biological significance of the newly described SCLC subtypes, SCLC-A, SCLC-N, SCLC-Y, and SCLC-P, defined by the dominant expression of transcription factors ASCL1, NeuroD1, YAP1, and POU2F3, respectively, remain to be established.

Methods

We generated new RNA sequencing expression data from a discovery set of 59 archival tumor samples of neuroendocrine tumors and new protein expression data by immunohistochemistry in 99 SCLC cases. We validated the findings from this discovery set in two independent validation sets consisting of RNA sequencing data generated from 51 SCLC cell lines and 81 primary human SCLC samples.

Results

We successfully classified 71.8% of SCLC and 18.5% of carcinoid cases in our discovery set into one of the four SCL

SUBMITTER: Owonikoko TK 

PROVIDER: S-EPMC7920957 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature